NYSEAMERICAN:OSTX OS Therapies (OSTX) Stock Price, News & Analysis $1.41 +0.02 (+1.44%) Closing price 04:10 PM EasternExtended Trading$1.42 +0.01 (+0.78%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About OS Therapies Stock (NYSEAMERICAN:OSTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get OS Therapies alerts:Sign Up Key Stats Today's Range$1.38▼$1.4450-Day Range$1.39▼$1.8852-Week Range$1.15▼$2.25Volume375,237 shsAverage Volume857,612 shsMarket Capitalization$65.04 millionP/E RatioN/ADividend YieldN/APrice Target$13.33Consensus RatingModerate Buy Company Overview OS Therapies, Inc. is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma and other solid tumors. The company’s work is directed toward cancer patients who have limited treatment options, with an emphasis on pediatric and young-adult oncology. OS Therapies’ lead investigational product is OST-HER2, an immunotherapy designed to stimulate the immune system to recognize and attack tumors that express the HER2 protein. The therapy is being developed primarily for osteosarcoma, a rare bone cancer, and remains investigational rather than an approved commercial treatment. The company’s activities include clinical development, oncology research and the advancement of additional potential therapies for solid tumors. OS Therapies is headquartered in the United States and has focused its development efforts on addressing significant unmet needs in cancer care.AI Generated. May Contain Errors. Read More OS Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreOSTX MarketRank™: 1.461789679945 of 5 starsOS Therapies scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingOS Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialOS Therapies has a consensus price target of $13.33, representing about 845.6% upside from its current price of $1.41.Amount of Analyst CoverageOS Therapies has received no research coverage in the past 90 days.Read more about OS Therapies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OS Therapies are expected to grow in the coming year, from ($0.73) to $0.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OS Therapies is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OS Therapies is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.22% of the float of OS Therapies has been sold short.Short Interest Ratio / Days to CoverOS Therapies has a short interest ratio ("days to cover") of 3.88, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OS Therapies has recently increased by 22.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOS Therapies does not currently pay a dividend.Dividend GrowthOS Therapies does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for OSTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OS Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders9.60% of the stock of OS Therapies is held by insiders.Percentage Held by InstitutionsOS Therapies has minimal institutional ownership at this time.Read more about OS Therapies' insider trading history. Receive OSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OS Therapies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OSTX Stock News HeadlinesRubenstein Public Relations Named Agency of Record for OS TherapiesOctober 8, 2026 | globenewswire.comOS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine OsteosarcomaOctober 7, 2026 | marketscreener.comMDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 15 at 1:00 AM | Stansberry Research (Ad)OS Therapies bolsters leadership team amid commercialization pushOctober 5, 2026 | tipranks.comOS Therapies, Inc. Announces Appointment of Kerry Clem as Chief Commercial OfficerOctober 2, 2026 | marketscreener.comMAnalysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Axalta Coating Systems (AXTA)September 22, 2026 | theglobeandmail.comOS Therapies Announces Prospectus for Secondary Share ResalesSeptember 10, 2026 | tipranks.comOS Therapies Stockholders Approve Incentive Plan and BoardSeptember 9, 2026 | tipranks.comSee More Headlines OSTX Stock Analysis - Frequently Asked Questions How have OSTX shares performed this year? OS Therapies' stock was trading at $1.40 at the beginning of the year. Since then, OSTX stock has increased by 0.7% and is now trading at $1.41. How were OS Therapies' earnings last quarter? OS Therapies Incorporated (NYSEAMERICAN:OSTX) posted its earnings results on Friday, August, 14th. The company reported ($0.20) EPS for the quarter. Who are OS Therapies' major shareholders? OS Therapies' top institutional investors include Sanders Morris Harris LLC (0.04%). View institutional ownership trends. How do I buy shares of OS Therapies? Shares of OSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OS Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that OS Therapies investors own include NVIDIA (NVDA), Super Micro Computer (SMCI), Archer Aviation (ACHR), Joby Aviation (JOBY), Oklo (OKLO), Taiwan Semiconductor Manufacturing (TSM) and Iovance Biotherapeutics (IOVA). Company Calendar Last Earnings8/14/2026Today10/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 OSTX's financial health is in the Green zone, according to TradeSmith. OSTX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:OSTX Previous SymbolNYSE:OSTX CIK1795091 Webostherapies.com Phone(410) 297-7793FaxN/AEmployees5Year Founded2018Price Target and Rating Average Price Target for OS Therapies$13.33 High Price Target$20.00 Low Price Target$7.00 Potential Upside/Downside+845.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.75 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-477.37% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-8.29Miscellaneous Outstanding Shares46,130,000Free Float41,698,000Market Cap$65.04 million OptionableN/A Beta-0.64 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NYSEAMERICAN:OSTX) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
